Short extension to NICE publication date

genedrive plc (AIM: GDR), the point-of-care pharmacogenetic testing company, acknowledges, as announced on 3 April 2024, that the UK's National Institute for Health and Care Excellence ("NICE") has recommended in draft guidance that CYP2C19 genotyping should be used to guide clopidogrel use after Ischaemic Stroke ("IS") or Transient Ischaemic Attack ("TIA"), and that the Genedrive® CYP2C19-ID test should be used as the test of choice for point-of-care strategies.

The final publication was expected by NICE on 10 July 2024, but the Company notes from the NICE website that this has recently been extended to 31 July 2024. Further details can be found at: https://www.nice.org.uk/guidance/indevelopment/gid-dg10054/documents.